<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466904</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI362A101</org_study_id>
    <nct_id>NCT04466904</nct_id>
  </id_info>
  <brief_title>Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM</brief_title>
  <official_title>A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is aimed to investigate the safety, tolerability, PK and PD of multiple
      subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor
      glycemic control after lifestyle or metformin intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled trial, the first trial to
      assess the safety, tolerability, and PK/PD of IBI362 administered as multiple injections in
      Chinese patients with type 2 diabetes. The investigators and subjects will be blinded to the
      study drug IBI362 and placebo. Dulaglutide will be used as an open-label active control
      group. In this trial, 42 eligible patients will be recruited and randomly allocated to three
      cohorts. Each corhot will be randomized as an 8:4:2 ratio to IBI362 (n = 8), placebo (n = 4),
      and Dulaglutide 1.5 mg (n = 2).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo</measure>
    <time_frame>From the first dose of study drug to week 19</time_frame>
    <description>Number of subjects with treatment emergent adverse events and serious adverse events through the end of the follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The PK/PD parameters of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Peak Plasma Concentration (Cmax) of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Area under the plasma concentration versus time curve (AUC) of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Fasting Blood Glucose (FBG ) of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Glucagon of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Insulin of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the C-peptide of IBI362 in patients with T2DM</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-IBI362 Antibodies</measure>
    <time_frame>From the first dose of study drug to week 19</time_frame>
    <description>Serum samples will be analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-IBI362 binding antibodies. Positive samples will be subsequently tested in a receptor-ligand binding bioassay for anti-IBI362 neutralizing antibodies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>IBI362 low dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 medium dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 high dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362</intervention_name>
    <description>Administrated by subcutaneous injection</description>
    <arm_group_label>IBI362 high dose cohort</arm_group_label>
    <arm_group_label>IBI362 low dose cohort</arm_group_label>
    <arm_group_label>IBI362 medium dose cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administrated by subcutaneous injection</description>
    <arm_group_label>IBI362 high dose cohort</arm_group_label>
    <arm_group_label>IBI362 low dose cohort</arm_group_label>
    <arm_group_label>IBI362 medium dose cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administrated by subcutaneous injection</description>
    <arm_group_label>IBI362 high dose cohort</arm_group_label>
    <arm_group_label>IBI362 low dose cohort</arm_group_label>
    <arm_group_label>IBI362 medium dose cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        * Eligibility Criteria： Inclusion Criiteria:

          1. Male or female 18 to 75 years of age at the time of consent.

          2. T2D patients with poorly controlled blood glucose treated with lifestyle intervention
             or stable dose of metformin (≥ 1000mg/day or maximum tolerated dose) within 2 months
             prior to screening.

          3. HbA1c 7.5% ≤ 11.0% by local laboratory at screening.

          4. Body mass index 20 ≤ BMI ≤ 35 kg/m2.

        Exclusion Criteria:

          1. Type 1 diabetes, special types of diabetes, or gestational diabetes.

          2. Ketoacidosis or lactic acidosis within 6 months prior to screening.

          3. History of severe hypoglycaemic episodes within 6 months prior to screening.

          4. Acute myocardial infarction, unstable angina pectoris, coronary artery bypass
             grafting, coronary intervention (except diagnostic angiography), transient ischemic
             attack (TIA), cerebrovascular accident, acute and chronic heart failure within 6
             months before screening.

          5. Clinically symptomatic liver disease, acute or chronic hepatitis, or transaminases
             (ALT and AST) and alkaline phosphatase (ALP) &gt; 2 times the upper limit of normal and
             total bilirubin above the upper limit of normal at screening.

          6. The patient was previously diagnosed with autonomic neuropathy, manifested as urinary
             retention, resting tachycardia, orthostatic hypotension and diabetic diarrhea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>chenghang cai</last_name>
    <phone>15921128917</phone>
    <email>chenghang.cai@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenying Yang Yang</last_name>
      <phone>010-84205718</phone>
      <email>Ywying_1010@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

